Bilateral exudative retinal detachment in the macula a few hours after oral administration of melanoma drugs — binimetinib and encorafenib: a case report
Abstract
Mitogen-activated extracellular signal-regulated kinase (MEK) inhibitor-associated retinopathy (MEKAR) is observed in oncological patients undergoing MEK inhibitor therapy, such as binimetinib and encorafenib. It is characterized by self-limiting accumulation of the subretinal fluid. MEKAR typically presents bilaterally, involving the fovea, and reveals characteristic optical coherence tomography (OCT) features compared to central serous chorioretinopathy (CSR), which may clinically resemble. Recent studies highlight that MEKAR often resolves without discontinuing the inhibitors. We report a case of a 55-year-old female with metastatic melanoma who developed MEKAR a few hours after administering binimetinib and encorafenib treatment. Progress in the development of oncological diseases’ pharmacological treatment, and consequently increased use of MEK inhibitors, should raise awareness among ophthalmologists regarding the management of patients with MEKAR and the importance of collaboration with oncologists.
Keywords: MEK inhibitor-associated retinopathy (MEKAR)BRAF 6V00E mutationbinimetinibencorafenibcentral serous chorioretinopathy (CSR)
References
- Zaleśna I, Hartman ML, Czyż M. [BRAF mutation in progression and therapy of melanoma, papillary thyroid carcinoma and colorectal adenocarcinoma]. Postepy Hig Med Dosw (Online). 2016; 70: 471–488.
- Potocki LP, Potocki PM, Wysocki PJ. BRAF — a new therapeutic target in colorectal cancer. Oncol Clin Pract. 2018; 14(2): 86–95.
- Francis JH, Habib LA, Abramson DH, et al. Clinical and Morphologic Characteristics of MEK Inhibitor-Associated Retinopathy: Differences from Central Serous Chorioretinopathy. Ophthalmology. 2017; 124(12): 1788–1798.
- Groselli S, Heinrich D, Lohmann CP, et al. MEK-Inhibitor-assoziierte Retinopathie unter Binimetinib-Therapie bei kutanem malignem Melanom. Der Ophthalmologe. 2020; 118(2): 169–174.
- Zhang X, Lim CZ, Chhablani J, et al. Central serous chorioretinopathy: updates in the pathogenesis, diagnosis and therapeutic strategies. Eye Vis (Lond). 2023; 10(1): 33.
- Zarnegar A, Ong J, Matsyaraja T, et al. Pathomechanisms in central serous chorioretinopathy: A recent update. Int J Retina Vitreous. 2023; 9(1): 3.
- Chancellor JR, Kilgore DA, Sallam AB, et al. A Case of Non-Resolving MEK Inhibitor-Associated Retinopathy. Case Rep Ophthalmol. 2019; 10(3): 334–338.